Source comparison
Melanotan-1 MC1R Agonism: Formulation Comparison
Different formulations of Melanotan-1 produce vastly different pharmacokinetic profiles and clinical outcomes. The table below compares the three primary delivery methods used in research and clinical settings. | Formulation Type | Dose & Frequency | Peak Plas
This comparison does not assign a generated winner or score.
- Different formulations of Melanotan-1 produce vastly different pharmacokinetic profiles and clinical outcomes. The table below compares the three primary delivery methods used in research and clinical settings.
- | Formulation Type | Dose & Frequency | Peak Plasma Concentration | Half-Life | MC1R Selectivity at Therapeutic Dose | Clinical Application | Professional Assessment ||—|—|—|—|—|—|| Subcutaneous controlled-release implant (Scenesse) | 16mg implant every 60 days | 200–400 pg/mL (sustained) | 33 hours (peptide), 60-day release | High. Minimal MC4R activation | FDA-approved for EPP; used in investigational trials for vitiligo and polymorphous light eruption (PMLE) | Gold standard for sustained MC1R agonism without off-target effects; eliminates user error in reconstitution or dosing || Lyophilized powder for reconstitution (research-grade) | 0.5–1.0mg SC injection daily | 2,000–5,000 pg/mL (transient peak at 30–60 min) | 33 hours | Moderate. Transient MC4R activation possible at peak | Research use; investigational photoprotection studies | Higher peak concentrations increase off-target risk but allow dose titration; requires precise reconstitution with bacteriostatic water and refrigerat